Ross said:
Granted, 1850 is insanely high,
I have great genetics indeed. Many 19-21 year olds will test that high though, which is why it is TRUE that teenagers don't need steroids!
I think this is something a lot of people overlook.
Personally, I don't think that taking advice from the 'genetic freaks' is always the best idea.
Genetic freaks can usually eat or train or eat any sort of diet and still put on muscle.
Those comments, 'well Jay/Ronnie/Flex did it this way', completely irrelevant to the majority of the population.
I have come to realise that the best advice and knowledge are from those who:
1. Are hardgainers/ectomorphs, have had to work hard to put on muscle (I think women are also in this category as well

)
2. Have pushed their physique to the max nattie, and then used or kept it nattie
This is an example of how you would post scientific papers on the internet so that people can actually find them and check out the original source themselves.
If you notice, aspirin doesn't work on everyone, so claims that some herbs can replace steroids is a bit over the top.
I also included the introduction as I thought it was interesting.
http://www.bmj.com/cgi/content/full...in&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT
BMJ 2008;336:195-198 (26 January), doi:10.1136/bmj.39430.529549.BE (published 17 January 2008)
Research
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis
George Krasopoulos, cardiovascular surgery fellow1, Stephanie J Brister, associate professor1, W Scott Beattie, R Fraser Elliot chair in cardiac anaesthesia2, Michael R Buchanan, professor3
1 University Health Network, Division of Cardiovascular Surgery, Toronto General Hospital, 2 University Health Network, Department of Anaesthesiology, Toronto General Hospital, 3 McMaster University, Department of Pathology and Molecular Medicine, Hamilton, ON, Canada L8S 4L8
Correspondence to: M R Buchanan
[email protected]
Objective To determine if there is a relation between aspirin "resistance" and clinical outcomes in patients with cardiovascular disease.
Design Systematic review and meta-analysis.
Data source Electronic literature search without language restrictions of four databases and hand search of bibliographies for other relevant articles.
Review methods Inclusion criteria included a test for platelet responsiveness and clinical outcomes. Aspirin resistance was assessed, using a variety of platelet function assays.
Results 20 studies totalling 2930 patients with cardiovascular disease were identified. Most studies used aspirin regimens, ranging from 75-325 mg daily, and six studies included adjunct antiplatelet therapy. Compliance was confirmed directly in 14 studies and by telephone or interviews in three. Information was insufficient to assess compliance in three studies. Overall, 810 patients (28%) were classified as aspirin resistant. A cardiovascular related event occurred in 41% of patients (odds ratio 3.85, 95% confidence interval 3.08 to 4.80), death in 5.7% (5.99, 2.28 to 15.72), and an acute coronary syndrome in 39.4% (4.06, 2.96 to 5.56). Aspirin resistant patients did not benefit from other antiplatelet treatment.
Conclusion Patients who are resistant to aspirin are at a greater risk of clinically important cardiovascular morbidity long term than patients who are sensitive to aspirin.
There is no debate that long term aspirin use attenuates the risks of myocardial infarction, stroke, and vascular related deaths in patients with cardiovascular disease,1 but a significant number of patients prescribed aspirin as antithrombotic therapy have major adverse vascular related events each year.2 Consequently other antiplatelet agents in addition to aspirin have been prescribed for certain patients.w16-w20
The major controversy about aspirin therapy is why particular patients do not benefit from such therapy and how they might be identified. It has been suggested that some patients require a higher dose of aspirin than is normally recommended to achieve the expected antiplatelet effect—for example, inhibition of platelet function or inhibition of platelet thromboxane A2 synthesis.3456 w10 It is unclear whether these patients simply receive too low an aspirin dose, are not compliant, have differing abilities to absorb aspirin, or have an underlying genetic disposition that renders aspirin ineffective.2 7891011 Such patients have been labelled aspirin "resistant"—that is, their platelets are not affected in the same way or are affected differently from the platelets of those who seem to benefit from aspirin therapy (aspirin "sensitive" patients with no subsequent adverse cardiovascular event).121314151617 w1 w4-w9 w11-w13 Little consistency exists about which measure should be used to identify patients who seem resistant to aspirin.121314151617 w1 w4-w9 w11-w13 Also, few studies have assessed the effect of aspirin resistance on clinically important outcomes.
We systematically reviewed studies of aspirin resistance and its effect on adverse cardiovascular outcomes. We hypothesised that aspirin resistance is real and is clinically relevant—that is, it significantly affects the risk of cardiovascular, cerebrovascular, and vascular related events.11 w6